Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M72.3Revenue $M28.2Net Margin (%)--Altman Z-Score4.7
Enterprise Value $M64.2EPS $-0.3Operating Margin %--Piotroski F-Score3
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yY
Price/Book1.510-y EBITDA Growth Rate %--Quick Ratio14.1Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio14.1Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-31.7Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-36.6Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M39.1ROIC % (ttm)-263.8Gross Margin Increase y-yN

Gurus Latest Trades with BLRX

Number of guru portfolios checked: 68.
No Entry found in the selected group of Gurus. You can

BLRX is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


BLRX: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Press Releases about BLRX :

Quarterly/Annual Reports about BLRX:

    News about BLRX:

    Articles On GuruFocus.com
    Analysts Positive on BioLineRx Ltd. Following Ph2 Testing Expansion for AML May 05 2015 
    Roth Capital Weighs In On 5 Biotech Stocks to Watch Apr 05 2015 

    More From Other Websites
    BioLineRx to Report First Quarter 2015 Results on May 18, 2015 May 11 2015
    BioLineRx to Report First Quarter 2015 Results on May 18, 2015 May 11 2015
    BioLineRx Initiates Expansion Stage of Phase 2 Clinical Trial for Novel Treatment for Acute Myeloid... May 04 2015
    BioLineRx Initiates Expansion Stage of Phase 2 Clinical Trial for Novel Treatment for Acute Myeloid... May 04 2015
    4 Stocks Under $10 Making Big Moves Apr 07 2015
    BIOLINERX LTD. Financials Mar 27 2015
    BioLineRx (BLRX) Looks Good: Stock Moves 9.1% Higher - Tale of the Tape Mar 25 2015
    BioLineRX stem cell leukaemia drug meets goals in early trial Mar 25 2015
    BioLineRx Reports Successful Top-Line Safety and Efficacy Results for Novel Stem Cell Mobilization... Mar 25 2015
    BioLineRx Reports Successful Top-Line Safety and Efficacy Results for Novel Stem Cell Mobilization... Mar 25 2015
    3 Stocks Under $10 Making Big Moves Higher Mar 24 2015
    BioLineRx Reports Year End 2014 Financial Results Mar 23 2015
    BioLineRx to Report Fourth Quarter and Year End 2014 Results on March 23, 2015 Mar 23 2015
    BioLineRx Reports Year End 2014 Financial Results Mar 23 2015
    BioLineRx to Report Fourth Quarter and Year End 2014 Results on March 23, 2015 Mar 17 2015
    BioLineRx Closes $28.75 Million Underwritten Public Offering of its American Depositary Shares Mar 15 2015
    BioLineRx Closes $28.75 Million Underwritten Public Offering of its American Depositary Shares Mar 11 2015
    BioLineRx’s Treatment for Type 1 Diabetes Effective in Preclinical Trials Mar 11 2015
    BioLineRx Prices $25 Million Underwritten Public Offering of its American Depositary Shares Mar 11 2015
    BioLineRx’s Treatment for Type 1 Diabetes Effective in Preclinical Trials Mar 11 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK